Construct for Tetracycline Inducible Podocyte Specific Gene Expression in Mice


The National Institutes of Health announces the generation of a construct by ligating 2.5kb human podocin promoter sequence to gene encoding reverse tetracycline-controlled transcriptional activator which enables tetracycline-inducible podocyte specific gene of interest expression with another construct consisting of tetracycline responsive element, minimal CMV promoter and gene of interest.

Podocytes are post-mitotic epithelial cells that are positioned on the exterior aspect of the glomerular capillary wall and contribute to the selective molecular permeability of glomeruli. Podocyte damage or dysfunction results in loss of the characteristic foot processes that normally interdigitate and form the selective permeability barriers composed of filtration slits bridged by slit diaphragms. Minimal damage causes proteinuria that in the case of minimal change disease can be reversed by steroid treatment. In focal segmental glomerulosclerosis, more severe loss of podocytes ultimately results in glomerulosclerosis. The podocyte-specific inducible transgene system can be used to identify factors that exacerbate or ameliorate podocyte injury, and can be used to express Cre-recombinase.

Potential Commercial Applications: Competitive Advantages:
  • This technology can be used for the study of renal disease.
 
  • The podocyte-specific inducible transgene system can be used to identify factors that exacerbate or ameliorate podocyte injury, and can be used to express Cre-recombinase.


Development Stage:
Pre-clinical

Inventors:

Jeffrey Kopp (NIDDK)  ➽ more inventions...


Intellectual Property:
Research Material — Patent protection has not been pursued for this technology.

[Note: The use of Tetracycline controllable expression systems is covered by a series of patents including US #5,464,758 and 5,814,618 which are proprietary to TET Systems GmbH & Co. KG. Interested parties are also advised to contact TET Systems, info@tetsystems.com or by electronic request at http://www.tetsystems.com/ip-licensing/licensing/for-profit-research/]

Publications:
Shigehara T, et al. PMID 12874453

Licensing Contact:
Vladimir Knezevic, M.D.
Email: vlado.knezevic@nih.gov
Phone: 301.443.5560

OTT Reference No: E-299-2007-0
Updated: Feb 23, 2016